Immunotherapy boost for tough breast cancer

This study tests whether adding the immunotherapy drug pembrolizumab to standard hormone therapy can help prevent recurrence in people with a rare, aggressive type of breast cancer called inflammatory breast cancer. Participants had hormone receptor-positive cancer that did not fully disappear after initial chemotherapy. The goal is to see if this combination improves how long people stay cancer-free after radiation treatment.